Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-2127107 dose-ranging placebo-controlled phase 2 study in ALS
NL-OMON45879Phase 2Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of reldesemtiv in amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND) (4 arms), sponsored by Cytokinetics. Primary endpoint: Change in percent predicted slow vital capacity. Started Aug 2018; status: active, not recruiting.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)motor neuron disease (MND)
Beyond the preview
Go deeper on NL-OMON45879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45879.